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CARCINOMA OF THE KIDNEY

Tumors of the upper urinary tract constitute 1%
to 2% of all cancers, and each year 11 ,000 new cases
are diagnosed in the United States. Approximately
half of these patients have metastatic disease at the
time of diagnosis. H ypernephroma, or renal cell carcinoma, was first described in 1863 by Grawitz. These
tumors arise from tubular epithelial cells and are
correctly termed renal cell carcinoma or renal cell
adenocarcinoma. There is evidence that further identifies the cell of origin as being from the proximal
convoluted tubular epithelium. There does not appear to be a specific racial or ethnic incidence although it occurs three times more often in men than
in women. Few epidemiological studies of this disease
have been undertaken, although there is some association between the use of tobacco and an increased
incidence of renal cell carcinoma. The classical triad
of hematuria, pain, and a palpable mass are late
findings with a poor prognosis which occurs in 10%
of the patients a nd usually represents metastatic disease. Forty percent of the patients may have hematuria or other urinary complaints. Local effects of the
tumors are hematuria, pain, and a flank mass, but the
presenting symptoms may include a varicocele in the
male which is produced by direct pressure of the
tumor on the spermatic vein or because of stasis

caused by an obstructing tumor thrombus in the vena
cava. Systemic toxic effects such as hyperpyrexia may
be of an intermittent or variable nature. Anemia or
abnormal liver chemistries may also be present.
Erythrocytosis, hypertension, and hypercalcemia
may also be manifest.
Once a renal mass is found, a number of procedures can be follo wed in order to evaluate the patient
before surgery. These include the use of intravenous
excretory urography, retrograde pyelography, nephrotomography, renal angiography, and venacavography, along with sonographic examination of renal
masses and the evaluation of renal masses by the use
of computerized axial tomography.
The staging cl assification developed by Robeson
is probably the most widely accepted: Stage I-tumor confined within the kidney; stage 2-perirenal
fat involvement confined within Gerota fascia; stage
3-a. gross renal vein or inferior vena cava involvement, b. lymphatic involvement, and c. vascular
and lymphatic involvement; stage 4-a. adjacent organs other than the adrenal involved, and b. distant
metastases. Renal vein involvement without perinephric involvement or lymphatic spread does not
seem to alter the prognosis at 5-10 years where lymphatic involvement is an ominous sign.
Treatment
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Surgical removal of the tumor for cure is the
basic management of the patient with hypernephroma. The single, most significant advance in
technique a nd its influence on survival were pointed
out in 1968 by Robeson, who used the combination
of early ligation of the renal artery and vein, complete
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removal of the perinephric envelope, and surgical
extirpation of the lymphatic field. Caution in handling of the renal vein is important, especially if there
is tumor involvement of the veins, as portions of
renal vein tumor may break off and cause acute pulmonary embolization.
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therapy for them is total removal of the kidney and
renal pelvis with removal of the entire ureter and a
cuff of bladder. For those people who have undergone only partial removal of the ureter, recurrence in
the stump of ureter has been high .
BLADDER CANCER

Preoperative Radiation
Several investigators have advocated the use of
preoperative radiation in the management of renal
cancer, but random clinical trials to date have not
shown that this has improved long-term survival. In
certain patients, however, a preoperative course of
radiotherapy of 3,000-4,000 rads to the kidney in four
weeks has markedly decreased the vascularity of the
tumor. There is some evidence that postoperative
radiotherapy may have a beneficial effect on survival
statistics, especially if there has been extracapsular
invasion and tumor has been left behind.
Chemotherapy
The use of chemotherapy in the management of
metastatic renal carcinoma has proven particularly
disappointing. Good results have been quoted by
some investigators with the use of medroxyprogesterone (Provera) 100 mg t.i.d . and a number of other
chemotherapeutic agents singly or in combination.
Special Management Problems
Involvement of the renal vein and vena cava are
of interest because of the possible use of extracorporal circulation in order to approach the patient
with tumor thrombus in the renal vein, the vena cava,
and the atrium of the heart.
Carcinoma arising in a solitary kidney provides
a real therapeutic dilemma. Procedures such as partial nephrectomy in situ, bench surgery with the removal of the kidney, perfusing the kidney for preservation, surgical excision of the tumor with repair of
the kidney and autotransplantation back into the
patient, and total extirpation with homotransplantation at a later date have all been used.
Approximately 12% of upper urinary tract malignancies are from renal pelvic tumors. These are
often transitional cell carcinomas, but a few are of the
squamous cell variety. The diagnosis is usually based
on the appearance of a filling defect on intravenous
urography or retrograde pyelography. A differential
diagnosis from a nonopaque stone or blood clot may
be difficult. As these tumors tend to be multiple, the

Carcinoma of the urinary bladder accounts for
4% to 5% of all new cancers. Approximately 30,000
new cases of bladder cancer are found in the United
States each year resulting in over 9,500 deaths. The
incidence is three times more prominent in men than
in women and four times more common in whites
than in non-whites. Age distribution reveals a peak in
patients 75-84 years of age, and 80% of these tumors
occur after age 50.
The known and suspected causes of bladder cancer are grouped into four categories: 1) Industrial
chemicals; 2) metabolites of foodstuffs; 3) tobacco
tar; and 4) chronic mechanical irritation and infection.
All but 3% to 4% of bladder tumors originate in
the transitional cell epithelium . Transitional cell carcinoma of the bladder occurs in approximately 90%
of the patients, with squamous cell carcinoma accounting for 6% to 7% and adenocarcinoma 1% to
2%. Transitional cell carcinomas may be very small
and papillary in character but may be multiple, large
and sessile tumors; the surface may be intact or ulcerated, crusted, and bleeding. Squamous cell cancer, on
the other hand, is usually flat, ulcerated, and sometimes necrotic; adenocarcinoma appears grossly as
transitional or squamous and must be differentiated
microscopically.
Diagnosis
Painless, gross hematuria is found in 75% to 85%
of the patients presenting with carcinoma of the bladder. As the tumor enlarges, other symptoms such as
frequency, urgency, dysuria, and decrease in caliber
or force of the urinary stream may be present. These
symptoms may be secondary to infection of the bladder or may be irritations caused by the tumor. As the
tumor progresses, the suprapubic pain and a palpable
mass may become prominent, these being associated
with obstructive uropathy and uremia.
The diagnosis is made at the time of cystoscopy
when a tumor is seen and biopsies can be obtained. It
is important that a rectal and bi-manual examination
be done to assess the size of the mass. A palpable,
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hard, indurated mass is usually a sign of an advanced
tumor and a poor prognosis.
Intravenous urography is an important step in
the assessment of the patient with bladder cancer.
The urogram will indicate the functional status of the
kidneys and the possibilities of ureteral obstruction.
By using triple-phase contrast studies of the bladder,
one can ascertain fixation of the bladder wall and the
possibility of invasion. If this is combined with pelvic
arteriography in conjunction with perivesical and intravesical gas or with computerized axial tomography, a better evaluation of the size of the tumor may
be found.
Grading and Staging

All tumors can be graded histologically based on
the degree of cellular anaplasia. Grade I or welldifferentiated tumor has a much better prognosis
than a grade III or IV or poorly differentiated tumor.
Staging in the United States has usually been by the
A, B, C, D classification of Jewett and Strong, and
Marshall. Recently the TNM (Tumor, Nodes, Metastasis) classification of the International Union
Against Cancer has been publicized in order to get
physicians in the United States to switch to that
classification of all tumors. In general, however, a
stage O tumor is one that is localized only to the
mucosa; stage A is limited to the submucosa, and
stage 8 1 indicates that the tumor has invaded the
bladder muscle but is less than half-way through the
bladder wall. Stage 8 2 tumors extend through the
bladder muscle but do not invade the perivesical fat,
and stage C indicates perivesical fat involvement or
involvement of the capsule of another organ. Stage
D, tumors are those that have spread to the regional
pelvic lymph nodes or have invaded the pelvic wall or
rectus muscle or both. Stage 0 2 tumors exist when
the tumor has spread beyond these limitations and is
outside the pelvis and the immediate bladder area.

Metastases occur most often to the regional lymph
nodes, lungs, liver, and bone.
Treatment

The treatment of the patient with a superficial
tumor is usually by means of endoscopic surgery with
transurethral resection. Careful follow-up examination with repeat cystoscopies every three months for
one year, and every six months for five years, and
every year thereafter are necessary in order that any
residual or recurrent tumors may be promptly found
and the appropriate treatment instituted. For the patient with multiple recurring tumors, the use of intravesical therapy (ThioTepa), partial or total removal
of the bladder, or radiation are possible therapeutic
choices. For the patient with invasive transitional cell
carcinoma, endoscopic procedures are not adequate.
One cannot endoscopically tell the degree and extent
of the tumor, therefore, an open surgical procedure
with remova l of the entire tumor or radiation therapy
is indicated. It would appear as of this writing, that
the best results are obtained from preoperative radiation followed by open surgical extirpation of the tumor, usually a radical cystectomy with urinary diversion. There is some discussion about whether 2,000
rads in one week , 4,000 rads in 4 weeks, or 4,500 rads
in 6 weeks followed by either immediate or delayed
cystectomy is best.
Chemotherapy

Long-term survival is rare once the tumor has
spread beyond the confines of the bladder. One
means of destroying metastases, however, may be
through the use of combinations of chemotherapeutic
agents. Drugs used in the management of patients
with transitional cell carcinoma of the bladder have
been 5-fluorourocil, bleyomycin, adriamycin, cyclophosphamide (Cytoxan) and the cis-platinum compounds.

